Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms

Blood

Volumn 115, Issue 4, 2010, Pages 879-886

  Duckers, Connie ^a   Simioni, Paolo ^b   Spiezia, Luca ^b   Radu, Claudia ^b   Dabrilli, Paolo ^b   Gavasso, Sabrina ^b   Rosing, Jan ^a   Castoldi, Elisabetta ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM IONOPHORE; COLLAGEN; THROMBIN; THROMBOCYTE ANTIGEN; THROMBOCYTE FACTOR 5; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; BLOOD CLOTTING FACTOR; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ADULT; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE FUNCTION; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; WESTERN BLOTTING; BIOSYNTHESIS; BLEEDING DISORDER; BLOOD; GENETICS; HOSPITALIZATION; IMMUNOPRECIPITATION; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADULT; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; FACTOR V DEFICIENCY; FEMALE; HEMORRHAGIC DISORDERS; HUMANS; IMMUNOPRECIPITATION; LIPOPROTEINS; MIDDLE AGED; MUTATION, MISSENSE; PLATELET ACTIVATION; SEVERITY OF ILLNESS INDEX; THROMBIN; YOUNG ADULT;

EID: 77949321986     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-237719     Document Type: Article

References (50)

1. Tracy PB, Eide LL, Bowie EJ, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60(1):59-63.
2. Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry. 1990;29(5):1118-1128.
3. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem. 1979; 254(21):10952-10962.
4. Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980;255(1):274-283.
5. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269(50):31869-31880. (Pubitemid 24379561)
6. Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270(36):21158-21166.
7. Gewirtz AM, Keefer M, Doshi K, Annamalai AE, Chiu HC, Colman RW. Biology of human megakaryocyte factor V. Blood. 1986;67(6):1639-1648.
8. Giampaolo A, Vulcano F, Macioce G, et al. Factor-V expression in platelets from human megakaryocytic culture. Br J Haematol. 2005; 128(1):108-111.
9. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood. 1998;92(9): 3035-3041. (Pubitemid 28492307)
10. Gould WR, Simioni P, Silveira JR, Tormene D, Kalafatis M, Tracy PB. Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet-derived cofactor. J Thromb Haemost. 2005;3(3): 450-456. (Pubitemid 41632868)
11. Thomassen MCLG, Castoldi E, Tans G, et al. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool. Haematologica. 2003;88(10):1150-1156. (Pubitemid 37362547)
12. Bouchard BA, Meisler NT, Nesheim ME, Liu CX, Strickland DK, Tracy PB. A unique function for LRP-1: a component of a two-receptor system mediating specific endocytosis of plasma-derived factor V by megakaryocytes. J Thromb Haemost. 2008;6(4):638-644.
13. Wencel-Drake JD, Dahlbäck B, White JG, Ginsberg MH. Ultrastructural localization of coagulation factor V in human platelets. Blood. 1986;68(1):244-249.
14. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem. 1995;270(35):20794-20800.
15. Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem. 2004; 279(4):2383-2393.
16. Camire RM, Kalafatis M, Simioni P, Girolami A, Tracy PB. Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood. 1998;91(8):2818-2829. (Pubitemid 28227532)
17. Duckers C, Simioni P, Rosing J, Castoldi E. Advances in understanding the bleeding diathesis in factor V deficiency. Br J Haematol. 2009;146(1): 17-26.
18. Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia. 2008;14(6):1164-1169.
19. Asselta R, Tenchini ML, Duga S. Inherited defects of coagulation factor V: the hemorrhagic side. J Thromb Haemost. 2006;4(1):26-34.
20. Vos HL. An online database of mutations and polymorphisms in and around the coagulation factor V gene. J Thromb Haemost. 2007;5(1): 185-188. Available online at: http://www.lumc.nl/rep/cod/redirect/4010/research/factor-v-gene.html.
21. Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol. 1998;103(4): 1067-1069. (Pubitemid 29012645)
22. Lee WS, Chong LA, Begum S, Abdullah WA, Koh MT, Lim EJ. Factor V inhibitor in neonatal intracranial hemorrhage secondary to severe congenital factor V deficiency. J Pediatr Hematol Oncol. 2001;23(4):244-246. (Pubitemid 32524930)
23. Salooja N, Martin P, Khair K, Liesner R, Hann I. Severe factor V deficiency and neonatal intracranial haemorrhage: a case report. Haemophilia. 2000;6(1):44-46. (Pubitemid 30113901)
24. Ellestad SC, Zimmerman SA, Thornburg C, Mitchell TE, Swamy GK, James AH. Severe factor V deficiency presenting with intracranial haemorrhage during gestation. Haemophilia. 2007;13(4):432-434. (Pubitemid 47040175)
25. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature. 1996;384(6604):66-68. (Pubitemid 26374587)
26. Yang TL, Cui J, Taylor JM, Yang A, Gruber SB, Ginsburg D. Rescue of fatal neonatal hemorrhage in factor V deficient mice by low level transgene expression. Thromb Haemost. 2000;83(1): 70-77. (Pubitemid 30045480)
27. Mann KG. How much factor V is enough?. Thromb Haemost. 2000;83(1):3-4.
28. Lunghi B, Pinotti M, Maestri I, Batorova A, Bernardi F. Evaluation of factor V mRNA to define the residual factor V expression levels in severe factor V deficiency. Haematologica. 2008;93(3): 477-478.
29. Duckers C, Simioni P, Spiezia L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood. 2008;112(9):3615-3623.
30. Al Dieri R, Peyvandi F, Santagostino E, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002;88(4):576-582. (Pubitemid 35173997)
31. Miletich JP, Majerus DW, Majerus PW. Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J Clin Invest. 1978;62(4):824-831.
32. Guasch JF, Cannegieter S, Reitsma PH, van't Veer-Korthof ET, Bertina RM. Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol. 1998;101(1): 32-39.
33. Ajzner EE, Balogh I, Szabo T, Marosi A, Haramura G, Muszbek L. Severe coagulation factor V deficiency caused by 2 novel frameshift mutations: 2952delT in exon 13 and 5493insG in exon 16 of factor 5 gene. Blood. 2002;99(2):702-705. (Pubitemid 34533112)
34. Shinozawa K, Amano K, Suzuki T, et al. Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency. Int J Hematol. 2007; 86(5):407-413.
35. Tognin G, Rossetto V, Barillari G, et al. Clinical and molecular characterization of three Italian patients with severe factor V deficiency and bleeding disorder ('Parahaemophilia'): report of a novel homozygous mutation (FV: Asp524His) [abstract]. J Thromb Haemost. 2005;3(suppl 1): P0250.
36. Chiriu A, Radu C, Tognin G, Spiezia L, Bulato C, Simioni P. Two novel factor V gene mutations in two parahaemophilic subjects [abstract]. Haematologica. 2008;93(suppl 3):P208.
37. Olds R, Simioni P, Thompson E, Morgan T, Girolami A, Lane D. Factor V Gly2112Asp, a C2-domain variant, is associated with severe deficiency and a bleeding tendency [abstract]. J Thromb Haemost. 2003;1(suppl 1):P1206.
38. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32(5-6): 249-253. (Pubitemid 37490547)
39. Nesheim ME, Nichols WL, Cole TL, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest. 1986;77(2): 405-415.
40. Monković DD, Tracy PB. Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem. 1990;265(28):17132-17140.
41. Bradford HN, Annamalai A, Doshi K, Colman RW. Factor V is activated and cleaved by platelet calpain: comparison with thrombin proteolysis. Blood. 1988;71(2):388-394.
42. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets. 2001;12(5):261-273. (Pubitemid 32730513)
43. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood. 1988;72(6): 2020-2025.
44. Maroney SA, Mast AE. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 2008;38(1):9-14.
45. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 1983;736(1): 57-66.
46. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415(6868):175-179. (Pubitemid 34059519)
47. Magdeleyns EJ, Keuren JF, Curvers J. Factor Va, bound to microparticles released during platelet storage, is resistant to inactivation by activated protein C. Transfusion. 2007;47(10):1880-1888. (Pubitemid 47438556)
48. Tracy PB, Mann KG. Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders. Hum Pathol. 1987;18(2):162-169.
49. Weiss HJ, Lages B, Zheng S, Hayward CP. Platelet factor V New York: a defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation. Am J Hematol. 2001; 66(2):130-139. (Pubitemid 32096628)
50. Mast AE, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood. 1996;87(5):1845-1850.